Theravance Biopharma, Inc. Balance Sheet
TBPH / Health Care|14 years of annual SEC 10-K data (FY2012-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 14 fiscal years. All figures from audited SEC 10-K filings.
Theravance Biopharma, Inc. had $486M in total assets and $297M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $167.8M | $37.8M | $39.5M | $298.2M | $90.0M | $81.5M | $378.0M | $89.0M | $89.0M | $344.7M | $0 | $0 | $0 | $0 |
| Accounts Receivable | - | - | - | - | - | - | - | $620.0K | $2.3M | $646.0K | $125.0K | $125.0K | $199.0K | - |
| Inventory | - | - | - | - | - | - | - | - | $16.8M | $12.2M | $14.3M | $14.3M | $10.4M | - |
| Current Assets | $418.5M | $161.1M | $133.5M | $353.5M | $249.9M | $393.3M | $338.5M | $532.8M | $378.7M | $528.5M | $237.5M | $275.4M | $14.1M | - |
| PP&E (Net) | $5.9M | $7.4M | $9.1M | $11.9M | $13.7M | $16.4M | $12.6M | $13.2M | $10.2M | $8.5M | $9.6M | $9.6M | $10.2M | - |
| Total Assets | $485.6M | $354.2M | $382.0M | $607.4M | $374.8M | $469.1M | $408.8M | $560.2M | $441.4M | $639.3M | $300.1M | $337.8M | $25.2M | - |
| Current Liabilities | $38.3M | $32.1M | $24.8M | $28.7M | $58.6M | $123.6M | $111.7M | $98.6M | $62.6M | $49.3M | $49.5M | $41.3M | $36.9M | - |
| Total Debt | - | - | $0 | - | $616.3M | $619.2M | $455.0M | $454.4M | $223.7M | - | - | - | - | - |
| Shareholders' Equity | $296.7M | $175.5M | $213.0M | -$338.6M | -$338.6M | -$303.8M | $115.2M | $350.2M | $115.2M | $350.2M | -$17.0M | -$7.0M | -$17.0M | -$7.0M |